Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06043947 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Survival Monitoring in Russian Cancer Registries

Study acronym: SURVIMON
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2024 to Dec 31, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2027
    v4
  2. Primary completion date changed from estimate of Dec 31, 2023 to Dec 31, 2024
    • Study completion date: Jan 31, 2024 to Dec 31, 2025
    v3
  3. Enrollment target: 10000 to 100000v2 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Eligibility criteria revised
    • Study description shortened, about 109 words
    • Collaborators expanded, about 5 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to establish a holistic framework for continuous cancer survival surveillance in Russian regions with high-quality population-based cancer registry data. The data from the population-based cancer registries of the Northwestern regions of Russia will be used to assess net and cause-specific survival trends.
Trial Details
NCT Number NCT06043947
Lead Sponsor N.N. Petrov National Medical Research Center of Oncology
Collaborators: European University at St. Petersburg
Conditions
(from sponsor)		 Melanoma, Breast Cancer, Oncology, Colon Cancer, Prostate Cancer, Survivorship, Lung Cancer, Cervix Cancer
Related terms Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Prostatic Neoplasms, Uterine Cervical Neoplasms
Enrollment 100,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov